본문 바로가기
KERD
논문KCI 등재

Mesenchymal Stem Cells Attenuate Asthmatic Inflammation and Airway Remodeling by Modulating Macrophages/Monocytes in the IL-13-Overexpressing Mouse Model

김유진|강혜련|Lee Chun-Geun|Elias Jack A.|모요셉|방지용|정지응
대한면역학회 (The Korean Association of Immunologists)|2022.10|Immune Network|제22권 제5호|pp. 1-24|DOI 10.4110/in.2022.22.e40

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

AsthmaMonocytesMesenchymal stem cellsMacrophagesInterleukin-13

초록

Mesenchymal stem cells (MSCs) are attractive alternatives to conventional anti-asthmatic drugs for severe asthma. Mechanisms underlying the anti-asthmatic effects of MSCs have not yet been elucidated. This study evaluated the anti-asthmatic effects of intravenously administered MSCs, focusing on macrophages and monocytes. Seven-week-old transgenic (Tg) mice with lung-specific overexpression of IL-13 were used to simulate chronic asthma. MSCs were intravenously administered four days before sampling. We examined changes in immune cell subpopulations, gene expression, and histological phenotypes. IL-13 Tg mice exhibited diverse features of chronic asthma, including severe type 2 inflammation, airway fibrosis, and mucus metaplasia. Intravenous administration of MSCs attenuated these asthmatic features just four days after a single treatment. MSC treatment significantly reduced SiglecF-CD11c-CD11b+ monocyte-derived macrophages (MoMs) and inhibited the polarization of MoMs into M2 macrophages, especially M2a and M2c. Furthermore, MSCs downregulated the excessive accumulation of Ly6c- monocytes in the lungs. While an intravenous adoptive transfer of Ly6c- monocytes promoted the infiltration of MoM and Th2 inflammation, that of MSC-exposed Ly6c- monocytes did not. Ex vivo Ly6c- MoMs upregulated M2-related genes, which were reduced by MSC treatment. Molecules secreted by Ly6c- MoMs from IL-13 Tg mice lungs upregulated the expression of fibrosis-related genes in fibroblasts, which were also suppressed by MSC treatment. In conclusion, intravenously administered MSCs attenuate asthma phenotypes of chronic asthma by modulating macrophages. Identifying M2 macrophage subtypes revealed that exposure to MSCs transforms the phenotype and function of macrophages. We suggest that Ly6c- monocytes could be a therapeutic target for asthma management.

Abstract

Mesenchymal stem cells (MSCs) are attractive alternatives to conventional anti-asthmatic drugs for severe asthma. Mechanisms underlying the anti-asthmatic effects of MSCs have not yet been elucidated. This study evaluated the anti-asthmatic effects of intravenously administered MSCs, focusing on macrophages and monocytes. Seven-week-old transgenic (Tg) mice with lung-specific overexpression of IL-13 were used to simulate chronic asthma. MSCs were intravenously administered four days before sampling. We examined changes in immune cell subpopulations, gene expression, and histological phenotypes. IL-13 Tg mice exhibited diverse features of chronic asthma, including severe type 2 inflammation, airway fibrosis, and mucus metaplasia. Intravenous administration of MSCs attenuated these asthmatic features just four days after a single treatment. MSC treatment significantly reduced SiglecF-CD11c-CD11b+ monocyte-derived macrophages (MoMs) and inhibited the polarization of MoMs into M2 macrophages, especially M2a and M2c. Furthermore, MSCs downregulated the excessive accumulation of Ly6c- monocytes in the lungs. While an intravenous adoptive transfer of Ly6c- monocytes promoted the infiltration of MoM and Th2 inflammation, that of MSC-exposed Ly6c- monocytes did not. Ex vivo Ly6c- MoMs upregulated M2-related genes, which were reduced by MSC treatment. Molecules secreted by Ly6c- MoMs from IL-13 Tg mice lungs upregulated the expression of fibrosis-related genes in fibroblasts, which were also suppressed by MSC treatment. In conclusion, intravenously administered MSCs attenuate asthma phenotypes of chronic asthma by modulating macrophages. Identifying M2 macrophage subtypes revealed that exposure to MSCs transforms the phenotype and function of macrophages. We suggest that Ly6c- monocytes could be a therapeutic target for asthma management.

참고문헌 (53)

  1. Stern J, "Asthma epidemiology and risk factors", Semin Immunopathol, 42, pp.5~15 (2020)
  2. Henderson I, "Why do some asthma patients respond poorly to glucocorticoid therapy", Pharmacol Res, 160, pp.105189~ (2020)
  3. Akkoç T, "Asthma immunotherapy and treatment approaches with mesenchymal stem cells", Immunotherapy, 12, pp.665~674 (2020)
  4. Dimarino AM, "Mesenchymal stem cells in tissue repair", Front Immunol, 4, pp.201~ (2013)
  5. Song N, "Mesenchymal stem cell immunomodulation : Mechanisms and therapeutic potential", Trends Pharmacol Sci, 41, pp.653~664 (2020)
  6. Jiang W, "Immune modulation by mesenchymal stem cells", Cell Prolif, 53, pp.e12712~ (2020)
  7. Mirershadi F, "Unraveling the therapeutic effects of mesenchymal stem cells in asthma", Stem Cell Res Ther, 11, pp.400~ (2020)
  8. Jae Woo Shin, "Mesenchymal Stem Cells Suppress Severe Asthma by Directly Regulating Th2 Cells and Type 2 Innate Lymphoid Cells", Molecules and Cells, 44(8), pp.580~590 (2021), 한국분자세포생물학회[DOI]
  9. Poston RN, "Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi", Am Rev Respir Dis, 145, pp.918~921 (1992)
  10. Tomita K, "Identification and characterization of monocyte subpopulations from patients with bronchial asthma", J Allergy Clin Immunol, 96, pp.230~238 (1995)
  11. Saradna A, "Macrophage polarization and allergic asthma", Transl Res, 191, pp.1~14 (2018)
  12. Guilliams M, "Establishment and maintenance of the macrophage niche", Immunity, 52, pp.434~451 (2020)
  13. Keyhanmanesh R, "Systemic delivery of mesenchymal stem cells condition media in repeated doses acts as magic bullets in restoring IFN-γ", IL-4balance in asthmatic rats, 2018, pp.212, 30~36
  14. Jeong EM, "Monitoring glutathione dynamics and heterogeneity in living stem cells", Int J Stem Cells, 12, pp.367~379 (2019)
  15. Jeong EM, "Real-time monitoring of glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function", Stem Cell Reports, 10, pp.600~614 (2018)
  16. Chang J, "Vitamin D suppresses bleomycininduced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung", Sci Rep, 11, pp.16525~ (2021)
  17. Hu X, "Protective effect of TM6 on LPSinduced acute lung injury in mice", Sci Rep, 7, pp.572~ (2017)
  18. Hu Z, "Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells", Cell Mol Immunol, 9, pp.267~275 (2012)
  19. Kim J, "Mesenchymal stem cell-educated macrophages : a novel type of alternatively activated macrophages", Exp Hematol, 37, pp.1445~1453 (2009)
  20. Khan DA, "Allergic rhinitis and asthma : epidemiology and common pathophysiology", Allergy Asthma Proc, 35, pp.357~361 (2014)
  21. Zhu Z, "Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production", J Clin Invest, 103, pp.779~788 (1999)
  22. Hou F, "Diversity of macrophages in lung homeostasis and diseases", Front Immunol, 12, pp.753940~ (2021)
  23. Rőszer T, "Understanding the mysterious M2 macrophage through activation markers and effector mechanisms", Mediators Inflamm, 2015, pp.816460~ (2015)
  24. Moreira AP, "Macrophages in allergic asthma : fine-tuning their pro-and antiinflammatory actions for disease resolution", J Interferon Cytokine Res, 31, pp.485~491 (2011)
  25. Tang Z, "Human umbilical cord mesenchymal stromal cells attenuate pulmonary fibrosis via regulatory T cell through interaction with macrophage", Stem Cell Res Ther, 12, pp.397~ (2021)
  26. Fang SB, "Small extracellular vesicles derived from human MSCs prevent allergic airway inflammation via immunomodulation on pulmonary macrophages", Cell Death Dis, 11, pp.409~ (2020)
  27. Murray LA, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P", Int J Biochem Cell Biol, 43, pp.154~162 (2011)
  28. Nouno T, "Elevation of pulmonary CD163+ and CD204+ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients", J Thorac Dis, 11, pp.4005~4017 (2019)
  29. Willis GR, "Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation", Am J Respir Crit Care Med, 197, pp.104~116 (2018)
  30. Luo XY, "Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes", Stem Cell Res Ther, 10, pp.16~ (2019)
  31. Braza F, "Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma", Stem Cells, 34, pp.1836~1845 (2016)
  32. Song X, "Mesenchymal stem cells alleviate experimental asthma by inducing polarization of alveolar macrophages", Inflammation, 38, pp.485~492 (2015)
  33. Abdelaziz MH, "Alternatively activated macrophages; a double-edged sword in allergic asthma", J Transl Med, 18, pp.58~ (2020)
  34. Yang J, "Monocyte and macrophage differentiation : circulation inflammatory monocyte as biomarker for inflammatory diseases", Biomark Res, 2, pp.1~ (2014)
  35. Misharin AV, "Nonclassical Ly6C(-)monocytes drive the development of inflammatory arthritis in mice", Cell Reports, 9, pp.591~604 (2014)
  36. Clements M, "Differential Ly6c expression after renal ischemia-reperfusion identifies unique macrophage populations", J Am Soc Nephrol, 27, pp.159~170 (2016)
  37. Melino M, "Spatiotemporal characterization of the cellular and molecular contributors to liver fibrosis in a murine hepatotoxic-injury model", Am J Pathol, 186, pp.524~538 (2016)
  38. Puchner A, "Non-classical monocytes as mediators of tissue destruction in arthritis", Ann Rheum Dis, 77, pp.1490~1497 (2018)
  39. Ko JH, "Mesenchymal stem", stromal cells precondition lung monocytes, Proc Natl Acad Sci U S A, pp.2016, 113[DOI]
  40. Zasłona Z, "Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthma", J Immunol, 193, pp.4245~4253 (2014)
  41. Yu X, "A narrative review of research advances in mesenchymal stem cell therapy for asthma", Ann Transl Med, 8, pp.1461~ (2020)
  42. Kim RL, "Mesenchymal stem cells exert their anti-asthmatic effects through macrophage modulation in a murine chronic asthma model", Sci Rep, 12, pp.9811~ (2022)
  43. Spaggiari GM, "MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs : central role of MSC-derived prostaglandin E2", Blood, 113, pp.6576~6583 (2009)
  44. Habibian R, "The effects of bone marrow-derived mesenchymal stem cells on ovalbumin-induced allergic asthma and cytokine responses in mice", Iran J Basic Med Sci, 21, pp.483~488 (2018)
  45. Najar M, "In vitro cellular and molecular interplay between human foreskin-derived mesenchymal stromal", stem cells and the Th17 cell pathway, 2021, pp.13, 1736~
  46. Obermajer N, "Conversion of Th17 into IL-17A(neg)regulatory T cells : a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy", J Immunol, 193, pp.4988~4999 (2014)
  47. Fang SB, "Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid celldominant allergic airway inflammation through delivery of miR-146a-5p", J Extracell Vesicles, 9, pp.1723260~ (2020)
  48. van Hoeven V, "Mesenchymal stromal cells stimulate the proliferation and il-22 production of group 3 innate lymphoid cells", J Immunol, 201, pp.1165~1173 (2018)
  49. Negi N, "Effects of mesenchymal stromal cells on regulatory T cells : Current understanding and clinical relevance", Stem Cells, 38, pp.596~605 (2020)
  50. Hayashi T, "Inhibition of experimental asthma by indoleamine 2, 3-dioxygenase", J Clin Invest, 114, pp.270~279 (2004)
  51. Hartert TV, "Prostaglandin E(2)decreases allergenstimulated release of prostaglandin D(2)in airways of subjects with asthma", Am J Respir Crit Care Med, 162, pp.637~640 (2000)
  52. Ankrum JA, "Mesenchymal stem cells : immune evasive, not immune privileged", Nat Biotechnol, 32, pp.252~260 (2014)
  53. Kavanagh H, "Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells", Allergy, 66, pp.523~531 (2011)

이 간행물의 다른 논문 (6건)

Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of ConceptOh Sangwook, Payne Aimee S.pp. 1-16Exosomal Communication Between the Tumor Microenvironment and Innate Immunity and Its Therapeutic Application김상범, 공현석pp. 1-24RNA Metabolism in T Lymphocytes함정현, 황수석, 최진욱pp. 1-181,3-Dibenzyl-5-Fluorouracil Prevents Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Differentiation유정은, Kim Taesoo, Jeon Hyoeun, Hwang Jung Me, Park Hye-Won, Yu Jiyeon, Lee Zee-Won, 노재랑pp. 1-12Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody이종길, 이영란, 박지현, 이희성, 박찬수, 김정기, 정재경, 이선재, 조현일, 김경제, 김상현pp. 1-20
원문 보기